Health And Human Services, Department Of- Food And Drug Administration- Fda Office Of Acq Grant Svcs
Health Research/ Animal Research
Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use- Induced Respiratory Depression In Vivo Validation - Title: Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use- Induced Respiratory Depression & mdash; In Vivo Validation Agency: U. S. Food and Drug Administration ( FDA) Notice Type: Presolicitation: Firm- Fixed Price
Preclinical assessment of naloxone adequacy to reverse polysubstance use- induced respiratory depression in vivo validation
Bid Close Date: